SCHEMBL4132813

SCHEMBL4132813

COc1ccc(F)cc1-c1ccc(O)c(C=C2SC(Nc3ccc(C(CCCCCC(=O)O)C(=O)O)cc3)=NC2=O)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMEL1 Q495T6 2/20 0.35
HPGD P15428 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MCL1 Q07820 1/20 0.35
CTSA P10619 8/20 0.34
ERN1 O75460 1/20 0.33
CISD1 Q9NZ45 1/20 0.32
ALOX5 P09917 2/20 0.32
F7 P08709 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HKDC1 Q2TB90 1/20 0.31
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31
ADRB3 P13945 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4132809 1.00 MMEL1 (0.35) MMEL1HPGDTDP1MEN1KMT2A
SCHEMBL4133913 0.82 CTSA (0.36) MMEL1HPGDTDP1MEN1KMT2A
SCHEMBL4133910 0.82 CTSA (0.36) MMEL1HPGDTDP1MEN1KMT2A
SCHEMBL4127922 0.80 CCNT1 (0.39) HPGDTDP1MEN1KMT2AMCL1
SCHEMBL4127918 0.80 CCNT1 (0.39) HPGDTDP1MEN1KMT2AMCL1
SCHEMBL4128676 0.80 PRMT5 (0.47) HPGDTDP1MEN1KMT2AMCL1
SCHEMBL4128679 0.80 PRMT5 (0.47) HPGDTDP1MEN1KMT2AMCL1
SCHEMBL4132687 0.80 CTSA (0.36) HPGDMEN1KMT2ACTSAERN1
SCHEMBL4132689 0.80 CTSA (0.36) HPGDMEN1KMT2ACTSAERN1
SCHEMBL4120885 0.76 HPGD (0.34) HPGDTDP1MEN1KMT2AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MMEL1 3424/4885HPGD 2231/4885TDP1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.